|Title||Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed|
|Authors||Sawada-Hirai, R., Jiang, I., Wang, F., Sun, S.M., Nedellec, R., Ruther, P., Alvarez, A., Millis, D., Morrow, P.R. and Kang, A.S.|
Background: Potent anthrax toxin neutralizing human monoclonal antibodies were generated from peripheral blood lymphocytes obtained from Anthrax Vaccine Adsorbed (AVA) immune donors. The anti-anthrax toxin human monoclonal antibodies were evaluated for neutralization of anthrax lethal toxin in vivo in the Fisher 344 rat bolus toxin challenge model.
Methods: Human peripheral blood lymphocytes from AVA immunized donors were engrafted into severe combined immunodeficient (SCID) mice. Vaccination with anthrax protective antigen and lethal factor produced a significant increase in antigen specific human IgG in the mouse serum. The antibody producing lymphocytes were immortalized by hybridoma formation. The genes encoding the protective antibodies were rescued and stable cell lines expressing full-length human immunoglobulin were established. The antibodies were characterized by; (1) surface plasmon resonance; (2) inhibition of toxin in an in vitro mouse macrophage cell line protection assay and (3) in vivo in a Fischer 344 bolus lethal toxin challenge model.
Results: The range of antibodies generated were diverse with evidence of extensive hyper mutation, and all were
of very high affinity for PA83~1 x 10-10-11M. Moreover all the antibodies were potent inhibitors of anthrax lethal
toxin in vitro. A single IV dose of AVP-21D9 or AVP-22G12 was found to confer full protection with as little as
0.5 x (AVP-21D9) and 1 x (AVP-22G12) molar equivalence relative to the anthrax toxin in the rat challenge
Conclusion: Here we describe a powerful technology to capture the recall antibody response to AVA vaccination and provide detailed molecular characterization of the protective human monoclonal antibodies. AVP-21D9, AVP-22G12 and AVP-1C6 protect rats from anthrax lethal toxin at low dose. Aglycosylated versions of the most potent antibodies are also protective in vivo, suggesting that lethal toxin neutralization is not Fc effector mediated. The protective effect of AVP-21D9 persists for at least one week in rats. These potent fully human anti-PA toxin-neutralizing antibodies are attractive candidates for prophylaxis and/or treatment against Anthrax Class A bioterrorism toxins.
|Journal||Journal of Immune Based Therapies and Vaccines|
|Journal citation||2 (5)|
|Digital Object Identifier (DOI)||https://doi.org/10.1186/1476-8518-2-5|